Use of substances with immunomodulating activity for the treatment of amyotrophic lateral sclerosis

Abstract

The present invention is directed to a method of treating a patient with amyotrophic lateral sclerosis using an effective amount of soluble Fcγ receptors. The soluble Fcγ receptors of the invention are specific for immunoglobulin G of under-class 1 (IgG1) and/or 3 (IgG3).

What is claimed is:  
     
         1 . A method of treating a patient with amyotrophic lateral sclerosis, said method comprising the steps of: 
 (a) administering to a patient with amyotrophic lateral sclerosis an effective amount of soluble Fcγ receptors, wherein said soluble Fcγ receptors bind to immunoglobulins in said patient to treat amyotrophic lateral sclerosis.    
     
     
         2 . The method of  claim 1 , wherein said soluble Fcγ receptors are FcγRIII receptors.  
     
     
         3 . The method of  claim 1 , wherein said immunoglobulins are immunoglobulins G of under-class 1 (IgG1) and/or 3 (IgG3).  
     
     
         4 . The method of  claim 1 , wherein said Fcγ receptors are administered at a concentration of between 10 and 60 μmol.  
     
     
         5 . The method of  claim 1 , wherein said administering is by infusion or injection.  
     
     
         6 . The method of  claim 1 , wherein said soluble Fcγ receptors binds to IgG1 to block FcγRIII receptor activity.  
     
     
         7 . The method of  claim 1 , wherein said soluble Fcγ receptors binds to IgG3 to block FcγRIII receptor activity.